Current revenues of antibody-based treatments are around $20 billion. However, independent market analyst Datamonitor has predicted that these revenues will grow by 14 percent a year between 2006 and 2012, making them the fastest-growing segment of the pharmaceuticals market.

Monoclonal antibodies, which are used in the treatment of cancer and rheumatoid arthritis, will surpass the annual growth rate of traditional small molecule drugs, which, due to generic competition, are expected to post growth rates of just 0.6 percent.

For more information, please see:  http://www.reuters.com/article/health-SP/idUSL1126194920071011